Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of the Glycoprotein IIb/IIIa Inhibition With Abciximab in Patients With ACS Undergoing Coronary Stenting After Pretreatment With a High Loading Dose of Clopidogrel (ISAR-REACT-2)

NCT00133003 Phase 4 COMPLETED

The purpose of this study is to determine whether there is any additional benefit from abciximab administration during percutaneous coronary intervention in patients presenting with acute coronary syndromes after pre-treatment with 600mg of clopidogrel.

Details

Lead sponsor	Deutsches Herzzentrum Muenchen
Phase	Phase 4
Status	COMPLETED
Enrolment	2022
Start date	2003-03
Completion	2006-01

Conditions

• Coronary Disease
• Angina, Unstable

Interventions

• Abciximab
• Placebo

Primary outcomes

• Composite rate of death, myocardial infarction, and urgent target vessel revascularization within 30 days — 30 days

Countries

Brazil, Germany, Netherlands